NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly EBIT Margin came in at 444.01% in Q1 2026, up 8.01% on a QoQ basis from 482.67% in Q4 2025.
NRX Pharmaceuticals (NRXP) EBIT Margin (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of EBIT Margin data on file, last reported at 444.01% in Q1 2026.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 444.01% in Q1 2026; TTM through Mar 2026 was 769.09%, a N/A change from a year earlier, with the FY2025 full-year figure at 1352.0%, changed N/A from the prior year.
- EBIT Margin for Q1 2026 stood at 444.01%, up from 482.67% in the prior quarter.
- Over the last five years, EBIT Margin for NRXP reached as high as 444.01% in Q1 2026 and fell as low as 2012.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 | -444.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -444.01% |
| Dec 31, 2025 | -482.67% |
| Sep 30, 2025 | -2,012.00% |